Biomarkers Consortium

Young research scientists



The FNIH Biomarkers Consortium has met a critical milestone that could improve clinical trials and accelerate treatment approvals for hospital-acquired bacterial infections.


The FNIH Biomarkers Consortium has launched a study to identify biological markers in the blood that will measure a Rheumatoid Arthritis (RA) patient’s increased risk for cardiovascular disease—the leading cause of deaths in RA patients.

Become a member of The Biomarkers Consortium today.

The Biomarkers Consortium is a public-private biomedical research partnership managed by the Foundation for the National Institutes of Health that endeavors to discover, develop, and seek regulatory approval for biological markers (biomarkers) to support new drug development, preventive medicine, and medical diagnostics.

The Biomarkers Consortium is helping create a new era of precision medicine, with more highly predictive markers that have an impact during a patient’s illness or lifespan. Our goal is to combine the forces of the public and private sectors to accelerate the development of biomarker-based technologies, medicines, and therapies for the prevention, early detection, diagnosis, and treatment of disease.

Front Page: